106 related articles for article (PubMed ID: 29781751)
1. Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities.
González J; Quiroga M; Escudero-Vilaplana V; Collado-Borrell R; Herranz-Alonso A; Sanjurjo Sáez M
Expert Opin Drug Saf; 2018 Jun; 17(6):553-572. PubMed ID: 29781751
[TBL] [Abstract][Full Text] [Related]
2. Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice.
Escudero-Vilaplana V; Revuelta-Herrero JL; Collado-Borrell R; Marzal-Alfaro B; Gimenez-Manzorro A; Herranz-Alonso A; Sanjurjo-Saez M
Expert Opin Drug Saf; 2019 Sep; 18(9):861-868. PubMed ID: 31282227
[No Abstract] [Full Text] [Related]
3. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients.
Villanueva-Bueno C; Escudero-Vilaplana V; Collado-Borrell R; Giménez-Manzorro Á; Ribed A; Marzal-Alfaro B; Revuelta-Herrero JL; Gonzalez-Haba E; Herranz A; Sanjurjo M
Expert Opin Drug Saf; 2022 Jan; 21(1):107-119. PubMed ID: 34357828
[TBL] [Abstract][Full Text] [Related]
4. Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents.
Ribed A; Escudero-Vilaplana V; Romero-Jimenez RM; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo-Saez M
Expert Opin Drug Saf; 2016; 15(4):427-35. PubMed ID: 26854363
[TBL] [Abstract][Full Text] [Related]
5. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.
Krens SD; Lassche G; Jansman FGA; Desar IME; Lankheet NAG; Burger DM; van Herpen CML; van Erp NP
Lancet Oncol; 2019 Apr; 20(4):e200-e207. PubMed ID: 30942181
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
Abou-Alfa GK; Lewis LD; LoRusso P; Maitland M; Chandra P; Cheeti S; Colburn D; Williams S; Simmons B; Graham RA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):29-36. PubMed ID: 28523596
[TBL] [Abstract][Full Text] [Related]
7. How adverse events and permanent medication stoppages affect changes in patients' beliefs about oral antineoplastic agents.
Marshall VK; Given CW; Sikorskii A; Given BA; Lehto RH
Support Care Cancer; 2020 Jun; 28(6):2589-2596. PubMed ID: 31529159
[TBL] [Abstract][Full Text] [Related]
8. Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe.
Lasala R; Santoleri F; Romagnoli A; Musicco F; Costantini A
Eur J Clin Pharmacol; 2019 May; 75(5):697-706. PubMed ID: 30617511
[TBL] [Abstract][Full Text] [Related]
9. A Concept Analysis of Oral Anticancer Agent Self-management.
Mason M; Harris MR; Greer JA; Jiang Y
Cancer Nurs; 2022 Mar-Apr 01; 45(2):E374-E387. PubMed ID: 33654013
[TBL] [Abstract][Full Text] [Related]
10. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
[TBL] [Abstract][Full Text] [Related]
11. Renal drug dosing recommendations: evaluation of product information for brands of the same drug.
Khanal A; Peterson GM; Castelino RL; Jose MD
Intern Med J; 2014 Jun; 44(6):591-6. PubMed ID: 24946814
[TBL] [Abstract][Full Text] [Related]
12. Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic hepatic impairment: analysis of the literature and recommendations.
Bodge MN; Culos KA; Haider SN; Thompson MS; Savani BN
Biol Blood Marrow Transplant; 2014 May; 20(5):622-9. PubMed ID: 24492142
[TBL] [Abstract][Full Text] [Related]
13. Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment.
Montesinos P; Rodríguez-Veiga R; Martínez-Cuadrón D; Boluda B; Navarro I; Vera B; Alonso CM; Sanz J; López-Chulia F; Martín G; Jannone R; Sanz G; Lancharro A; Cano I; Palau J; Lorenzo I; Jarque I; Salavert M; Ramírez P; Sanz MÁ
Rev Iberoam Micol; 2015; 32(3):185-9. PubMed ID: 25858598
[TBL] [Abstract][Full Text] [Related]
14. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
Guzzi LM; McCollum DA; Hursting MJ
J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents.
Escudero-Vilaplana V; Ribed A; Romero-Jimenez RM; Herranz-Alonso A; Sanjurjo-Saez M
Eur J Cancer Care (Engl); 2017 May; 26(3):. PubMed ID: 26872286
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
Tan AR; Sarantopoulos J; Lee L; Reyderman L; He Y; Olivo M; Goel S
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1051-61. PubMed ID: 26433580
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.
Devriese LA; Witteveen PE; Mergui-Roelvink M; Smith DA; Lewis LD; Mendelson DS; Bang YJ; Chung HC; Dar MM; Huitema AD; Beijnen JH; Voest EE; Schellens JH
Br J Clin Pharmacol; 2015 Aug; 80(2):253-66. PubMed ID: 25677219
[TBL] [Abstract][Full Text] [Related]
18. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
[TBL] [Abstract][Full Text] [Related]
19. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
Calvert AH; Alison DL; Harland SJ; Robinson BA; Jackman AL; Jones TR; Newell DR; Siddik ZH; Wiltshaw E; McElwain TJ
J Clin Oncol; 1986 Aug; 4(8):1245-52. PubMed ID: 3734849
[TBL] [Abstract][Full Text] [Related]
20. Renal complications in oncohematologic patients.
Buemi M; Fazio MR; Bolignano D; Coppolino G; Donato V; Lacquaniti A; Mondello S; Buemi A; Allegra A
J Investig Med; 2009 Dec; 57(8):892-901. PubMed ID: 19952895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
